Azurity Pharmaceuticals, Inc. - Company Research Report

Company Overview

• Name: Azurity Pharmaceuticals, Inc.

• Mission: Serving overlooked patients by developing dose-form innovations of established medicines for those with unmet needs.

• Founded: No information is available

• Founders: No information is available

• Key People in the Company:

• Richard Blackburn, Chief Executive Officer

• Hanok George, Chief Legal, Compliance & HR Officer

• Madan Mohan Rao, Vice President – Quality

• Ronald L. Scarboro, Chief Financial Officer

• Evan Scullin, Chief Medical Officer

• Ajay Singh, Chief Scientific Officer

• Terrence Terifay, Chief Commercial Officer

• Brian Wojick, Chief Digital and Information Officer

• Board of Directors:

• Nailesh Bhatt, Board Member

• Richard Blackburn, Chief Executive Officer

• Vern Davenport, Board Member

• Jeff Edwards, Board Member

• Frank Leo, Board Member

• Amit Patel, Executive Chairman

• Dave Ritchie, Board Member

• Headquarters: Woburn, Massachusetts

• Number of Employees: No information is available

• Revenue: No information is available

• Known for: Azurity is recognized for providing innovative, high-quality medicines serving overlooked patients, with a wide range of products treating cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective, and oncology conditions.

Products

Azurity Pharmaceuticals offers a comprehensive array of products, including:

• MYHIBBIN™ - Mycophenolate mofetil oral suspension

• Description: An antimetabolite immunosuppressant to prevent organ rejection.

• Key Features: FDA-approved, ready-to-use oral liquid formulation for adult and pediatric patients post kidney, heart, or liver transplants.

• NYMALIZE® - Nimodipine oral solution

• Description: Used for improving neurological outcomes in adult subarachnoid hemorrhage patients.

• Key Features: Available in prefilled ENFit® syringes, helps reduce risk from nimodipine capsule extraction.

Several other products, such as ADTHYZA®, BIDIL®, EDARBI®, FIRVANQ®, and ZONISADE™, span therapeutic areas from anti-infective to oncology.

Recent Developments

• FDA Approval of Nymalize:

• Date: September 3, 2024

• An innovative nimodipine oral solution, available in prefilled ENFit® syringes.

• FDA Approval of Myhibbin:

• Date: May 6, 2024

• This formulation is the only ready-to-use mycophenolate mofetil oral suspension approved.

• Acquisition of Slayback Pharma:

• Date: September 27, 2023

• A strategic enhancement expected to boost Azurity's capacity to innovate.

• Product Launches and Partnerships:

• Azurity continues to bring new FDA-approved medicines to market focusing on dose-form innovations to aid overlooked conditions.

• Product Recall:

• Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg was recalled in January 2024 due to labeling errors.

Azurity Pharmaceuticals, Inc. continues to excel in providing innovative medical solutions. With ongoing development projects and a commitment to serving overlooked patients, Azurity remains a pivotal player in the pharmaceutical industry.